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18F-Sodium fluoride (Na18F) is a radiopharmaceutical used for diagnosis in nuclear medicine by 
positron emission tomography (PET) imaging. Bone scintigraphy is normally performed using 99mTc-
MDP. However, 18F PET scans promise high quality imaging with increased resolution and improved 
sensitivity and specificity. In order to make available a tool for more specific studies of tumors and non-
oncological diseases of bone tissue, the UPPR/CDTN team undertook the production and quality control 
of Na18F injectable solution with the physical-chemical, microbiological and biological characteristics 
recommended in the U.S. Pharmacopeia. Na18F radiochemical purity was 96.7 ± 1.3 %, with Rf= 0.026 
± 0.006. The product presented a pH of 5.3 ± 0.6, half life of 109.0 ± 0.8 minutes, endotoxin limit < 5.0 
EU.mL-1 and no microbial contaminants. The biodistribution of Na18F was similar to that described in 
the literature, with a clearance of 0.19 mL.min-1 and distribution volume of 18.76 mL. The highest bone 
concentration (5.0 ± 0.5 %ID.g-1) was observed 20 minutes after injection. Na18F produced at the UPPR 
presented all the quality assurance requirements of the U.S. Pharmacopeia and can be safely used for 
clinical bone imaging.
Uniterms: Radiopharmaceuticals/biodistribution. Sodium fluoride 18F/production. Sodium fluoride 18F/
quality control. Sodium fluoride. 18F/dosimetry. Bone imaging.
O Fluoreto de sódio 18F (Na18F) é um radiofármaco empregado para diagnóstico através da Tomografia 
por Emissão de Pósitrons (PET). Cintilografias ósseas são normalmente obtidas utilizando-se 99mTc-MDP. 
Entretanto, o interesse pelo Na18F é crescente, principalmente devido à obtanção de imagens de elevada 
resolução. Com o objetivo de tornar disponível uma ferramenta mais específica para estudos de tumores 
e doenças não-oncológicas do tecido ósseo, o grupo da UPPR/CDTN implementou a produção e o 
controle de qualidade da solução injetável de Na18F com as características físico-química, microbiológica 
e biológica preconizadas pela farmacopéia. Sua pureza radioquímica foi de 96,7 ± 1,3 %, com Rf= 0,026 
± 0,006. O produto apresentou pH igual a 5,3 ± 0,6, tempo de meia-vida de 109,0 ± 0,8 minutos, limite de 
endotoxinas < 5,0 EU.mL-1 e ausência de microrganismos. O perfil de biodistribuição em camundongos 
foi semelhante ao disponível na literatura, com depuração igual a 0,19 mL.min-1 e volume de distribuição 
igual a 18,76 mL. A concentração máxima (5,0 ± 0,5 % DI.g-1) foi observada no osso 20 minutos após 
a injeção. O Na18F produzido na UPPR do CDTN apresentou os parâmetros de qualidade definidos na 
farmacopéia americana e pode ser usado com segurança para uso clínico em cintilografia óssea.
Unitermos: Radiofármacos/biodistribuição. Fluoreto de sódio. 18F/produção. Fluoreto de sódio. 18F/
controle de qualidade. Fluoreto de sódio. 18F/dosimetria. Cintilografia óssea. 
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INTRODUCTION
18F-Sodium fluoride injection (Na18F), a positron-
emitting radiopharmaceutical containing no carrier-added 
(NCA), is used for diagnostic purposes in conjunction 
with positron emission tomography (PET) imaging. 
This radiopharmaceutical became widely used for bone 
scintigraphy after its introduction by Blau et al. (1962) in 
the early 1960s and was approved for clinical use by the 
U.S. Food and Drug Administration in 1972. The use of 
99mTc-MDP has been brought into question given the ad-
vantages of PET imaging and the limited global supply of 
technetium-99m (99mTc). Moreover, bone uptake of Na18F 
is 2-fold greater than that of 99mTc-MDP and 18F-fluoride 
PET is more accurate than planar imaging or SPECT for 
localizing and characterizing bone lesions (Blau et al., 
1962).
The radiopharmaceutical Na18F has the desirable 
pharmacokinetics properties of high and rapid bone uptake 
coupled with very rapid blood clearance, which results in a 
high bone-to-background ratio within a short time frame. 
After intravenous administration, 18F-fluoride diffuses 
through the bone capillaries into the bone’s extracellular 
fluid (ECF). From the bone ECF, 18F-fluoride ions ex-
change with hydroxyl groups in the hydroxyapatite at the 
surface of bone crystals forming fluoroapatite mainly at 
sites of bone remodelling with high turnover. Therefore, 
uptake of 18F-fluoride reflects blood flow and osteoblastic 
activity (Grant et al., 2008).
18F-fluoride PET is a highly sensitive imaging modal-
ity for detection of benign and malignant osseous abnor-
malities and allows the regional characterization of lesions 
in metabolic bone diseases. Using hybrid PET/CT systems 
improves the specificity of 18F-fluoride PET in cancer 
patients by accurately differentiating between benign and 
malignant sites of uptake (Grant et al., 2008). The clinical 
usefulness of 18F-fluoride PET has been demonstrated for 
monitoring the response to therapy against a wide range of 
clinical indications such as osteoporosis, Paget’s disease, 
compression fractures, marrow lesion, stress injuries and 
many other abnormal bone activities (Bridges et al., 2007).
Given the applicability of Na18F for bone imaging 
has been confirmed, our objective was to obtain a high 
quality product. The commercial delivery system used 
for 18F-FDG can also be used for the efficient delivery of 
other 18F-labeled radiopharmaceuticals, including Na18F. 
Microbiological, physical-chemical and biological qual-
ity control tests were performed, and the Na18F injectable 
solution met the quality control requirements contained 
in the United States Pharmacopeia (USP 31). It is now 
feasible to perform high-quality Na18F bone scans in most 
nuclear medicine departments, contributing to bone dis-
order and tumour diagnoses. This radiopharmaceutical is 
available for clinical use in PET/CT imaging.
All drug manufacture and quality control complied 
with Current Good Manufacturing Practice regulations 
described in the regulatory requirements and general 
guidance published by the Brazilian Regulatory Agency 
for Medicines (ANVISA).
MATERIALS AND METHODS
Na18F Production
18F-Fluoride was produced on a 16.5 MeV Cyclotron 
PETtrace® (GE Healthcare) by the 18O (p,n)18F nuclear 
reaction. The niobium target (with yield of 215 mCi/μASat) 
was filled with 2.2 mL of enriched O18 water, which was 
irradiated with protons for 10 minutes at an intensity of 
25 µA. The solution containing 18F- was transferred into 
an automatic synthesis module, TracerLab® MXFDG (GE 
Healthcare), modified and prepared with reagents kit and 
accessories for Na18F production (Figure1). 18F-fluoride ions 
were trapped in a SepPak Light Accell, Plus QMA, anion 
exchange column and were then eluted with NaCl 0.9% so-
lution. Finally, the resulting 15 mL of Na18F was dispensed 
into sterile, pyrogen-free vials, through a 0.22 μm filter, 
in an automated dispensing unit (Theodorico, Comecer®).
Physical-chemical quality control
The pH value of Na18F was measured using pH paper 
(0-14) which displayed a different colour depending on the 
pH range of the samples. The results were compared with 
standard pH buffer and the estimated value was registered.
Radiochemical identity and purity of Na18F were 
confirmed either by thin layer chromatography (TLC) ac-
cording to Nandy et al. (2007) or using a high-performance 
liquid chromatography (HPLC) system.
FIGURE 1 - Graphic of general purpose fluorination module.
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The TLC stationary phase was silica gel and the 
mobile phase was acetonitrile : water (95:5% v/v). The ra-
dioactivity was determined by scanning the TLC SG plate 
with a suitable collimated radiation detector (Minigita star 
beta detector, Raytest®). The main peak was analyzed to 
define the retention factor (Rf) value and the radioactivity 
related to the sample, that must lie between 0.0 - 0.12 and 
be no less than 95%, respectively.
HPLC analyses were performed on a chromatogra-
phic system (Agilent®), connected in serie with a gamma 
detector (Raytest®). The anion-exchange column (Shi-
madzu, IC.A1) (size: 46 mm x 10 cm) temperature was 
kept constant at 25 °C. The flow rate was 1.0 mL.min-1, 
the sample volume was 20 µL and the solvent system was 
NaOH 0.1M (pH = 4.0). 
Radionuclidic purity was evaluated by gamma-ray 
spectrometry (Camberra Multichannel Analyzer). Half-life 
of 18F was calculated after measuring the radioactivity de-
cay of the sample over a 20-minute period in a radioisotope 
dose calibrator (Capintec CRC®-25R). The equation used 
is showed below:
  (1)
Where: A0= initial activity; A = activity measured 
after 20 minutes; t = time interval (in minutes) between 
the two measures (tA-tAo); t½ = half-life.
Microbiological quality control
Bacterial endotoxins were quantified by the chromo-
genic method, using an Endosafe® Portable Test System 
– PTS. This device includes a pumping system, a portable 
spectrophotometer and internal software to calculate sam-
ple data. Na18F samples in duplicate (previously diluted) 
were applied inside cartridges in parallel with positive 
control testing. The product was considered apyrogenic 
when the endotoxins level was no more than 11.6 EU.mL-1
The sterility of the Na18F solution was assayed perfor-
ming a test by direct inoculation of Na18F solution in trypti-
case soy broth and fluid thioglycollate medium. The test was 
performed in duplicate and a negative control test was also 
performed. The culture media were incubated at 25 °C and 
37 °C, respectively, and verified daily over a fourteen-day 
period. The product was considered sterile when there was 
no evidence of microbiological growth.
Physiological quality control
The Na18F physiological quality control was done by 
biodistribution studies in animals. Female Swiss mice with 
a body weight of around 25 g purchased from the Animal 
House Center (CEBIO) of the Biological Sciences Insti-
tute (ICB/UFMG). Mice were maintained on a light-dark 
cycle (12-h light, 12-h dark) at a room temperature of 25 
°C and given food and water ad libitum. Animal experi-
ments were performed in compliance with the Institute 
of Laboratory Animal Resources – Commission on Life 
Sciences – National Research Council, Washington, D.C. 
and the Brazilian society in science of Laboratory Animals 
(SBCAL).
Doses of 70 kBq of Na18F were injected by in-
travenous route into Swiss mice. After different time 
intervals (2.5 - 60 minutes), the animals were sacrificed. 
Blood samples were taken, and the thyroid, heart, lungs, 
liver, spleen, pancreas, kidneys, stomach, intestine, bone, 
muscle, brain and bladder removed and weighed. Their 
respective radioactivity was measured in an automatic 
gamma spectrometer (1480 Wizard 3’’– Wallac – Count-
ing efficiency for 0.511MeV: 48%). The biodistribution 
was evaluated after calculating the percentage uptake of 
injected dose per gram of organ (% DI.g-1).
Pharmacokinetics parameters were estimated by 
the Biexp Pharmacokinetics program (Murphy,R., Inaoe 
tonantzindra, Puebla, México 1991).
Radiation dosimetry
The absorbed radiation dose for each mouse organ 
was calculated applying MIRD formalism (Snyder et 
al., 1978) to the biodistribution results, according to the 
relations:
  (2)
  (3)
Where: Ãhis the cumulated activity in the target 
organ; S(rk←rh) is the mean absorbed dose in the target 
organ per unit of cumulated activity in the source organ; 
Di s the mean energy emitted; ϕi(rk←rh) is the absorbed 
energy fraction; m is the target tissue mass.
A value of ϕ = 1 (non-penetrating radiation) was 
adopted for the 18F positron emission radionuclide. The 
experimental results of the cumulated activity in the mice 
organs were extrapolated to humans, assuming a similar 
concentration ratio among various tissues between mouse 
and patient. This extrapolation converted mouse %ID.g-1 
data by adjusting organ mass difference between mouse 
M. B. Silveira, M. A. Soares, E. S. Valente, S. S. Waquil, A. V. Ferreira, R. G. Santos, J. B. Silva566
and patient (Kirschner et al., 1975 and Shen et al., 2005):
  (4)
Where: [A0]HO is the activity in the human organ; 
[A0]MO is the activity in the mouse organ; MHO is the human 
organ mass; MH is the human mass; mM is the mouse mass; 
mMO is the mouse organ mass.
This extrapolation was based on the organ masses 
of mouse used in the experiments and the adult human 
organ masses of the Cristy-Eckerman phantom (Cristy, 
Eckerman, 1987).
RESULTS AND DISCUSSION
Na18F production
Enriched water H2
18O was successfully irradiated on 
the Cyclotron. 18F- was produced by the nuclear reaction 
180 (p,n) 18F, by irradiation with protons for 10 minutes at 
the intensity of 25 µA. Na18F was produced in high yields 
of 87.3 ± 6.1%. Samples of the final product were sent to 
the quality control laboratories in appropriately shielded 
containers.
Physical-chemical and microbiological quality 
control
Na18F physical-chemical and microbiological 
characteristics were evaluated. The analyses described 
earlier determined its radiochemical identity and purity, 
radionuclidic identity and purity, pH, bacterial endotoxins 
and sterility.
The quality requirements used for Na18F were in 
accordance with those found in the United States Pharma-
copeia (USP 31), supplemented with literature data (Nandy 
et al.., 2007) (Table I).
Radiochemical purity of the Na18F solution was as-
sessed by thin-layer chromatography (TLC). The product 
migration profile was determined by scanning the chroma-
togram plate with a suitable collimated radiation detector 
(the radiochromatogram is represented in Figure 2).
The main peak on the radiochromatogram obtained 
using HPLC for the Na18F test solution had approximately 
the same retention time (about 2 minutes) as the peak for 18F 
described in literature data (Olberg et al., 2008). More than 
99% of the radioactivity was related to 18F peak (Figure 3).
The final product, analyzed by gamma spectrometry, 
presented high radionuclidic purity. The spectrum obtained 
(Figure 4) shows one main peak at 0.511 MeV, an usual 
energy level for a positron annihilation product.
Energy
The results of the tests performed on the PTS were 
TABLE I - Results obtained after testing Na18F microbiological, physical-chemical and biological properties (1 USP 31; 2 Nandy et 
al., 2007)
Tests Quality Requirements 
(USP 31 and Nandy et al., 2007)
Results
pH1 Between 4.5 and 8.0 5.3 ± 0.6
Radiochemical Identity2 0.00 < Rf ≥ 0.12 0.026 ± 0.006
Radiochemical Purity1 ≥ 95.0 % 96.7 ± 1.3%
Radionuclidic Identity1 Between 105 and 115 minutes. 109.0 ± 0.8 minutes
Radionuclidic Purity1 Main peak = 0.511 MeV Main peak = 0.511 MeV
Bacterial endotoxins1 ≤ 11.6 EU.mL-1 < 5.0 EU.mL-1
Sterility1 Sterile Sterile
FIGURE 2 - TLC scan of Na18F in 95:5 ACN: H2O mobile phase: 
Rf max = 0.05.
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FIGURE 3 - HPLC chromatogram of Na18F solution showing 
its radiochemical purity, using NaOH 0.1M as mobile phase.
FIGURE 4 - Gamma spectrum obtained with a suitable detector 
to determine Na18F radionuclidic purity. Main peak can be 
observed at 0.511 MeV.
in compliance with the requirements established by the 
USP 31, showing that the samples contained less than 
5.0 EU.mL-1. 
All the samples assayed for sterility were observed 
for 14 days and none showed evidence of microbiological 
growth. Therefore, the Na18F solutions were considered 
sterile.
Biological quality control
The biological quality control of Na18F was carried 
out through biodistribution studies in Swiss female mice. 
70 kBq of Na18F were injected in mice via the intravenous 
route and, after different time intervals (2.5 - 60 minutes), 
the animals were sacrificed and radiopharmaceutical dis-
tribution in the organs was calculated as percentage uptake 
of injected dose per gram of organ (%ID.g1). 
The biodistribution profile is shown in Figure 5 and 
FIGURE 5 - Na18F biodistribution profile in Swiss female mice. 
70 kBq of Na18F were injected into mice (i.v). After different 
time intervals, the animals were sacrificed, blood samples were 
taken, and thyroid, heart, lungs, liver, spleen, pancreas, kidneys, 
stomach, intestine, bone, muscle, brain and bladder were 
removed. Organ radioactivity was measured in an automatic 
gamma spectrometer and data were expressed as the percentage 
of total injected dose by tissue weight (% ID.g-1).
the results indicated that the blood concentration of the 
radiopharmaceutical was quickly reduced in the first hour 
post injection (4.50 ± 0.35 % ID.mL-1) (Figure 6a). 18F-
Sodium fluoride presented biexponential blood clearance 
with half-life of 5.1 minutes in the fast distribution phase 
and 87 minutes in the slow elimination phase. The Na18F 
clearance was 0.19 mL.min-1 and the distribution volume 
was 18.76 mL.
The Na18F kinetics in the main vital organs followed 
blood kinetics, and the radiopharmaceutical was rapidly 
cleared out. The only exception was bone kinetics, where 
the Na18F concentration increased during the time period, 
reaching a peak (5.0 ± 0.5 % ID.g-1) 20 minutes after the 
injection (Figure 6b).
Radiation dosimetry
Dosimetric studies aimed to evaluate the safety of 
the 18F-Sodium fluoride produced in the UPPR/CDTN for 
bone scintigraphy. The results (Table II) demonstrated that 
the highest absorbed doses in the mice were in bladder 
(11.5 mGy.70 KBq-1) and bone (7.1 mGy.70 KBq-1). Ab-
sorbed doses for the other organs were significantly lower, 
ranging from 1.3 - 4.0 mGy.70 KBq-1. The radiation doses 
extrapolated to patients indicated that radiation doses in 
bone and bladder were 13.6 and 21.9 mGy.370 MBq-1, 
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respectively. These results are quite similar to those pu-
blished by ICPR53 and show that Na18F produced at the 
UPPR/CDTN can be safely used for clinical bone imaging.
CONCLUSIONS
The automated synthesis of Na18F and its availabil-
ity was successfully accomplished using the commercial 
18FDG synthesizer TracerLab® MXFDG. The final solution 
presented high quality in accordance with the requirements 
of the USP 31. The biodistribution of Na18F was similar 
to that described in the literature and absorbed doses in 
organs were lower than radioprotection limits.
Considering the clinical importance of 18F-Sodium 
fluoride and the high resolution PET images provided by it, 
the UPPR group wish to start Na18F production and make 
it widely available. This study showed that the product 
presents good quality and meet the needs of hospitals, 
clinics, and research facilities. The radiopharmaceutical 
Na18F was produced according to the regulatory require-
ments and general guidance of Good Manufacturing 
Practices, published by the Brazilian Regulatory Agency 
for Medicines (ANVISA).
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FIGURE 6 - Na18F kinetics in blood (A) and bone (B).
TABLE II - Organ absorbed dose in mice and extrapolated to patients. The results were compared with literature data (ICRP 53). 
*Values were converted to clinically used doses (370 MBq)
Organ Absorbed doses in mice 
(Gy.70 Kbq-1)
Extrapolated dose to patients 
(Gy.370 MBq-1)
Patient dose ICRP data*
Thyroid 2.70x10-3 5.14x10-3 -
Heart 4.06x10-3 7.73 x10-3 1.44 x10-3
Lungs 2.27x10-3 4.33 x10-3 1.51 x10-3
Liver 1.32x10-3 2.52 x10-3 1.48 x10-3
Spleen 3.49x10-3 6.65 x10-3 -
Pancreas 3.08x10-3 5.86 x10-3 1.77 x10-3
Kidneys 3.04x10-3 5.80 x10-3 7.03 x10-3
Stomach 1.63x10-3 3.10 x10-3 1.40 x10-3
Intestine 2.54x10-3 4.84 x10-3 2.44 x10-3
Bone 7.14x10-3 1.36 x10-2 2.22 x10-2
Brain 1.56x10-3 2.98 x10-3 2.01 x10-3
Bladder 1.10x10-2 2.19x10-2 9.25x10-2
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